He has experienced more than 400 cases of ERCP, more than 300/100 cases of EUS/EUS-FNA/B per year since 2003 and His research interests are development of novel therapy for advanced pancreatic cancer and cholangiocarcinoma and also identification of novel biomarkers (predictive or prognostic) related to early diagnosis or long-term outcome of pancreatic cancer and cholangiocarcinoma. Recently, he participates in global GWAS study of pancreatic cancer sponsored by NCI (Bethesda, USA) as one of core members. Moreover, he is conducting development of liquid-biopsy driven biomarkers (ctDNA/proteomic marker/immunologic marker) for early diagnosis and monitoring of pancreatic cancer or cholangiocarcinoma. Recently, he finished phase I clinical trial (adenovirus-medicated double suicide gene therapy) in locally advanced pancreatic cancer successfully and now recently started phase II clinical trial using the gene therapy for locally advanced pancreatic cancer at 2021. Another phase 1 trial in advanced pancreatic cancer using novel egent (PAUF-MoAb) will be started soon. He is also conducting development of predictive biomarker for chemotherapy in pancreatic cancer using cancer tissue by WES and WTS.